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ABSTRACT
Signiﬁcant progress has been made to advance stem cell products as potential therapies for kidney
diseases: various kinds of stem cells can restore renal function in preclinical models of acute and
chronic kidney injury. Nonetheless this literature contains contradictory results, and for this reason, we
focus this review on reasons for apparent discrepancies in the literature, because they contribute to
difﬁculty in translating renal regenerative therapies. Differences in methodologies used to derive and
culture stem cells, even those from the same source, in addition to the lack of standardized renal dis-
ease animal models (both acute and chronic), are important considerations underlying contradictory
results in the literature. We propose that harmonized rigorous protocols for characterization, handling,
and delivery of stem cells in vivo could signiﬁcantly advance the ﬁeld, and present details of some sug-
gested approaches to foster translation in the ﬁeld of renal regeneration. Our goal is to encourage
coordination of methodologies (standardization) and long-lasting collaborations to improve protocols
and models to lead to reproducible, interpretable, high-quality preclinical data. This approach will cer-
tainly increase our chance to 1 day offer stem cell therapeutic options for patients with all-too-
common renal diseases. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:82–92
SIGNIFICANCE STATEMENT
This review reports an update on the use of stem cells for renal regeneration. It is proposed
that harmonized rigorous protocols for characterization, handling, and delivery of stem cells in
vivo could signiﬁcantly advance the ﬁeld of translational renal therapies.
INTRODUCTION
Both preclinical reports and clinical trials of stem
cells used for treatment kidney disease are
increasing rapidly. Different types of stem cells,
ranging from mesenchymal stem cells (MSCs) [1,
2], adipose stem cells (AdSCs) [3], amniotic ﬂuid
stem cells (AFSCs) [4, 5], renal progenitors (RPs)
[6, 7], and so forth, can stimulate renal repair
in vivo in models of acute and chronic kidney
failure. These stem cells act in part as modula-
tors of ﬁbrotic/inﬂammatory pathways and stim-
ulate endogenous regeneration and repair
mechanisms. Nonetheless, translation of renal
stem cell therapies appears to be somewhat
stalled, prompting us to re-evaluate the litera-
ture with an eye toward methodological details.
We highlight a variety of stem cell approaches
in preclinical development for acute kidney injury
(AKI) and chronic kidney disease (CKD). Our goal is
to provide examples of seemingly contradictory
results and evaluate differences and similarities
between studies. From this analysis, we provide
our opinion for the most promising paths forward
for the use of stem cells in renal regeneration and
to speed translation of these cells. The activation
of endogenous renal cells for kidney regeneration,
embryonic and pluripotent stem cells for the gen-
eration of renal organoids, and kidney-on-a-chip
technologies are not included in this analysis, and
readers are referred to relevant interesting reviews
[8, 9]. Similarly, pluripotent stem cells used to cre-
ate nephron organoids [10] and more complex kid-
ney organoids [11, 12] are not discussed. We also
do not address the myriad engineered adjuncts to
stem cell therapies, or genetically manipulated
stem cells or renal tissue engineering.
DIFFERENT TYPES OF STEM CELLS AND
PRECLINICAL MODELS OF RENAL DAMAGE
In this section, we will highlight different stem
cell types and animal models of AKI and CKD.
Several different populations of human and
murine resident RPs, both adult and embry-
onic, have been studied for renal regeneration.
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STANDARDS, PROTOCOLS, POLICIES, AND REGULATIONS
FOR CELL-BASED THERAPIES
or adult kidneys) provide protection in murine models of acute
tubular and glomerular damage [6, 13]. Administration of
CD133+ human cells reportedly limited ﬁbrosis after AKI and
promoted erythropoietin production [13]. Similar cells can be
obtained from urine of adult humans [14]. Human fetal
kidney-derived NCAM+ progenitors administered into kidney
parenchyma in a NOD/SCID mouse model of CKD created by
nephrectomy of 5/6 of the kidney mass (5/6 Nx) engrafted,
mediated improved creatinine clearance, and reduced ﬁbrosis
[15]. Interestingly, RPs co-expressing stromal and epithelial
markers in urine of preterm neonates seem to be a readily
available source for similar cells [16]. Many different types of
progenitor cells of mouse/rat origin have been isolated using
slow-cycling properties of stem cells or by stem cell marker
expression and demonstrate beneﬁcial effects in acute and
chronic models of renal damage [17].
A number of studies examined resident populations of mes-
enchymal stromal cells (MSC) from glomeruli and renal intersti-
tium. When compared with nonrenal MSC, the resident
population has a more nephrogenic gene expression proﬁle,
suggesting propensity to transdifferentiate or differentiate into
renal cells under appropriate cues. Indeed, they can differenti-
ate not only into renal epithelial cells but also into
erythropoietin-producing ﬁbroblasts and juxtaglomerular cells
containing renin granules [18]. Nestin+ renal MSC mediate res-
cue of AKI in mice, reducing serum creatinine and blood urea
nitrogen (BUN) levels, and host apoptotic events. Paracrine pro-
tective effects of this population include vascular endothelial
growth factor (VEGF) signaling, essential in maintaining the glo-
merular basement membrane [19]. These kidney-derived cells
are unlikely to be developed for autologous use as the popula-
tion is exhausted over the course of progression of CKD.
MSCs of nonrenal origin (bone marrow, adipose tissue, pla-
centa, cord and blood) are the most studied cells in animal
models of AKI and CKD. In AKI, either induced by toxic agents
such as cisplatin or glycerol, by sepsis, or by ischemia–
reperfusion (I-R) , MSCs have shown protective and regenera-
tive effects [20]. In CKD, accumulating experimental evidence
indicates that MSC treatment can reduce ﬁbrosis and renal
dysfunction [21]. MSCs limited CKD progression in 5/6 Nx
models [22] and ameliorated glomerular pathology in rodent
models of diabetic nephropathy [23, 24]. A meta-analysis per-
formed in 2015 showed that administration of bone marrow-
derived MSCs [compared with induced-pluripotent stem cells
(iPSCs) or organ-speciﬁc MSC)] were most effective cell type in
slowing development and progression of CKD [25]. Reduction
of BUN and improved glomerulosclerosis and interstitial ﬁbro-
sis pathologies were the most relevant changes observed after
MSC therapy. After glomerular damage induced by adriamycin
[26] MSCs can improve glomerular function. In addition to
amelioration of renal morphological abnormalities and
decreased proteinuria, pathological inﬂammation and micro-
vessel rarefaction can also be improved by MSCs [27].
Therapeutic signals in preclinical models were also obtained
using adipose-derived MSCs (AdMSCs). These cells have been
tested in most models of AKI, and the results are encouraging
[28, 29]. A stromal vascular fraction (SVF) can be isolated from
adipose and directly administered without culture, making
“same surgical procedure” possible for anticipated autologous
approaches. (It is important to note that isolation of SVF, which
requires centrifugation steps and usually enzymatic digestion
makes these cells “more than minimally manipulated” by FDA
guidance.) SVF-mediated renoprotective effects are similar to
those of cultured adipose MSCs in a rat model of I/R injury
[30]. MSCs from cord blood show similar effects to bone mar-
row MSCs in models of both AKI and CKD [31].
MSCs from older renal failure patients can be used autolo-
gously, but their therapeutic efﬁcacy may be blunted with age
(and disease). The complex disease pathological milieu is
known to affect MSC function such that MSCs from uremic or
diabetic patients are likely to be less effective therapeutically
[32, 33] compared to that of MSCs from healthy donors.
Endothelial progenitor cells (EPCs) from marrow or periph-
eral blood also have therapeutic potential in renal disease.
EPCs mainly act by promoting neovasculogenesis, via both
paracrine signaling and in situ differentiation into mature
endothelial cells. In pigs, EPCs ameliorated postischemic injury
due to renal arterial stenosis [34]. However, when directly
compared with MSCs, the renoprotective effect of EPCs was
slightly inferior. In rat models of glomerulosclerosis, unfractio-
nated bone marrow-derived cells (BMDCs, containing MSCs
and precursors of EPCs) ameliorated disease by engrafting into
the microvasculature of the glomerulus, suggesting that the
potential of BMDCs to differentiate toward endothelial line-
ages confers rescue [35]. Similar to MSCs, BMDCs from dis-
eased animals can shift toward a smooth muscle/
myoﬁbroblast progenitor cell lineage, reducing their efﬁcacy.
Maintaining the balance between SPCs and EPCs and mobiliz-
ing, recruiting, homing, and engrafting endothelial-committed
cells are complex goals for optimizing EPC therapies [35].
Although regeneration of the vasculature of an entire organ
continues to be challenging, EPCs are capable of preserving
existing microvasculature [36]. The relative advantages of
lineage-restricted EPCs versus MSCs with greater differentia-
tion potential are likely to be kidney disease type-speciﬁc and
are not yet deﬁned.
We demonstrated that stem cells derived from amniotic
ﬂuid are renoprotective in animal models of glycerol-induced
AKI, as well as CKD [4, 37]. AFSC seem to protect tubular and
glomerular cells by stimulating endogenous repair mecha-
nisms, thus reducing inﬂammation and ﬁbrosis [38]. Other
groups showed that these cells enhance recovery in 5/6 Nx
models and cisplatin-induced toxicity [39].
iPSCs are another attractive (potentially patient speciﬁc)
source of cells for treating kidney disease. Morigi’s group
reported that administration of human iPSCs, differentiated
toward nephrogenic intermediate mesoderm and then meta-
nephric mesenchyme, could engraft and promote recovery
from cisplatin-induced AKI [40]. Similar beneﬁcial results were
obtained in a mouse renal I/R model. Human iPSC-derived RPs
transplanted under the kidney capsule limited renal dysfunc-
tion and ﬁbrosis development [41]. Less work has been per-
formed with ESCs in the context of renal failure. Nevertheless,
encapsulated mouse ESCs transplanted onto the omentum slo-
wed progression of renal disease in a rat 5/6 Nx model [42].
Although not an exhaustive list of stem cell-based
approaches to preclinical kidney disease, the aforementioned
studies highlight diversity in the source, the characterization, the
application, and the mechanism of action of stem cells; the diver-
sity of species studied and disease models. Table 1 is a summary
of types of stem cells used, route of delivery, and disease models
and species for experimental renal disease therapies.
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Table 1. Summary of stem cell therapy models for kidney disease
Model Species Cell Route References
Acute kidney injury
I/R Mouse Glomerular progenitors and tubular progenitors IV [45]
I/R Mouse Mouse clonal renal MSC IV [18]
I/R Mouse Nestin+ kidney MSC IV [19]
I/R Sheep Autologous BM-MSC Renal artery [48]
Kidney autotx (I/R) Pig Autologous AF-MSC Renal artery [4]
I/R Rat AdMSC IV [29]
I/R Rat hAdSVF, hAdMSC Renal parenchyma [30]
I/R Mouse hiPSC-RPs (OSR1+ SIX2+) Renal capsule [41]
I/R Rat c-kit+ renal cells IP, intraaortic [101]
Ureter obstruction Rat rADSC IV [28]
Sepsis Rat Autologous AdMSC IV [102]
Glycerol Mouse hCD133+ RPs IV [13]
Glycerol Mouse hCD133+CD24+ progenitors IV [55]
Glycerol Mouse hAFSC Renal parenchyma [38]
Glycerol Mouse hMSC-microvesicles IV [44]
Glycerol Mouse hBM-MSC IV [70]
Cisplatin Mouse mBM-MSC IV [20]
Cisplatin Mouse hUC-MSC IV [31]
Cisplatin Mouse hiPSC-RPs IV [40]
Cisplatin Rat hAF-MSC IV [39]





Cisplatin Rat hCD133+ kidney cells IV [53]
Cisplatin Macaque Autologous BM-MSC Intraarterial [49]
Adriamycin Mouse EPC (in hydrogel) SC in ear Renal capsule [103]
Adriamycin Rat rBM-MSC IV [26]
Gentamycin Dog cUC-MSC Renal parenchyma [104]
Chronic kidney disease
Renal artery stenosis Pig Pig MSC, EPC Renal artery [34]
Renal artery stenosis Pig Autologous EPC Renal artery [36]
RAS with metabolic syndrome Pig Autologous MSC-EV Renal artery [105]
5/6 Nx Mouse Human NCAM+ RPs Renal parenchyma [15]
5/6 Nx Rat rBM-MSC IV [22, 27]
5/6 Nx Rat mESC Gel-on renal remnant
Gel-on omentum
[42]
5/6 Nx Rat rBM-MSC
hiPSC
Renal parenchyma [106]
Alport syndrome Mouse AFSC Intracardiac [5]
Alport syndrome Mouse AFSC-EV Intracardiac [43]
Lupus nephritis Mouse hESC-MSC IV [61]
Spontaneous CKD Cat Allo-AdMSC IV [50]
Diabetic nephropathy Mouse mAFSC Renal parenchyma [72]
Diabetic nephropathy Mouse hBM-MSC Intracardiac [23]
Diabetic nephropathy Mouse mBM-MSC IV [24]
Diabetic nephropathy Rat rBM-MSC Renal artery [107]
Examples highlighting the wide range of preclinical models and species studied in the context of stem cell therapies for kidney disease. Routes of
delivery are constrained by animal model and change biodistribution, so are noted here. Abbreviations: I/R, ischemia reperfusion; autotx,
autotransplantation; IP, intraperitoneal; RAS, renal artery stenosis; Nx, nephrectomy; MSC, mesenchymal stem cell; BM, bone marrow; AF,
amniotic ﬂuid; Ad, adipose; SVF, stromal vascular fraction; iPSC, induced pluripotent stem cell; ADSC, adipose-derived stem cell; UC, umbilical
cord; EPC, endothelial progenitor cell; SC, stem cells; EV, extracellular vesicles; RPs, renal progenitor; AdMSC, adipose-derived MSC; AFSC, amniotic
ﬂuid stem cells Before a stem cell type; h, human; m, mouse; c, canine; r, rat; allo, allogeneic.
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INTERPRETING REPORTS OF STEM CELL THERAPIES FOR KIDNEY
DISEASE
It is generally accepted that the renoprotective activity of stem
cells (both in acute and chronic renal disease models) is due
to stem cell secretion of cytokines and other molecules that
inhibit inﬂammation and ﬁbrosis and promote endogenous
repair processes including angiogenesis. Lately, several groups
including ours demonstrated that a major mechanism of action
of stem cells is via secretion of extracellular vesicles (EVs)
[43–45]. When taken up by host renal cells, EVs can transfer
genetic information that promotes regenerative processes. We
also demonstrated that EVs can “trap” ligands on EV mem-
brane surface receptors. For example, VEGF is trapped by sur-
face VEGF receptors on AFSC-derived EVs, thus sequestering
VEGF away from host glomerular cell receptors, which inhibits
pathological VEGF signaling involved in perpetuating renal
injury [43]. More details on the mechanisms of action of stem
cells can be found in Refs. [46, 47].
A general bottleneck in the ﬁeld is the apparent difﬁculty
in reproducing rodent studies in larger animal models (cats,
sheep). A careful look at these studies suggest that the sources
of cells and the details of the animal models in part account
for this problem, in addition to distinct renal physiology based
on species. For instance, after ovine I/R injury, autologous
MSCs did not provide therapeutic beneﬁt [48], which would
have been expected from similar rodent studies. Likewise, in
the rhesus monkey, MSC administration ameliorated AKI
induced by cisplatin to some extent but did not reverse estab-
lished interstitial ﬁbrosis [49]. Autologous AdMSCs have been
the primary cell source used in feline preclinical models, but
none of the studies have been able to replicate the efﬁcacy
reported in rodents [50, 51]. Differences between rodent and
feline kidneys certainly explain some of these results, which
are discouraging as feline CKD more closely resembles human
pathology. Feline MSCs have been characterized [52] but not
rigorously compared with rodent or human MSCs.
IMPORTANT VARIABLES IN THE PRECLINICAL RENAL
REGENERATION LITERATURE
Stem Cell Source, Isolation, and Culture
Standardized protocols for the characterization, identity, cul-
ture, and differentiation of the many stem cell types used in
renal regeneration research are not yet fully established. For
example, Santeramo et al. raised the issue of speciﬁcity of RPs
by showing a similar degree of renal regeneration induced by
both CD133+ and CD133− cells [53]. Similar results were
obtained using NCAM+ and NCAM− cells, raising questions
about whether RP cells, regardless of speciﬁc identity, promote
tissue repair similarly to differentiated cells [15]. Another
interpretation of these ﬁndings is that more detailed identity
markers are required, to have identity and efﬁcacy correlate.
However, a deeper look into the Methods section suggests
that more than identity markers are different: cell source,
selection, and culture are not consistent across studies. In our
opinion, it is extremely important to account for these meth-
odological differences, because they may lead to functional
differences in ability to rescue diseased kidneys. Speciﬁcally, it
is evident that the CD133+ cells used by Santeramo are
different than those used by Bussolati or by Romagnani [54,
55]: First, cell sources are different (infant kidneys vs. the
tubular component of adult kidney vs. nephrectomy tissue
vs. urine). In addition, the CD133+ cells are either sorted out
from cell culture or expanded as an unselected cell population,
with cell–cell signaling during expansion certainly impacted by
these methodological differences. Many different cell types
can express CD133, meaning that again a single marker is
probably insufﬁcient to identify a particular stem cell type.
Second, CD133+ cells are also usually positive for the renal-
speciﬁc marker, CD24. (Santeramo and Bussolati, unlike
Romagnani, do not select speciﬁcally for CD24.) Together
these reports suggest that CD133+/CD24+ cells are different
from, or a speciﬁc subset of, cells identiﬁed by CD133+ alone.
As in other aspects of preclinical stem cell studies, it is
extremely important to consider the relationship of passage
number to the phenotype of cells.
The same issues are important in comparing stem cells
derived from amniotic ﬂuid (AFSCs). In this case, the gesta-
tional age is an important variable. We derive AFSCs from dis-
carded amniocentesis samples during the ﬁrst trimester;
others collect cells at delivery, obtaining fresh ﬂuid samples
but late in gestation [37]. We also believe that clonal isolation
of the AFSCs is important for limiting heterogeneity of the cell
product. We used a clonal population of AFSCs after positive
selection for c-kit. Other groups use AFSCs derived from
colony-forming units or with no selection for any markers [37].
These methodologies for source and derivation of AFSCs could
account for the resultant differences in the ﬁnal product popu-
lation and functional differences in repair capacity.
The derivation and isolation of AdMSCs are complicated by
disparate sources of adipose tissue. For example, AdMSCs
derived subcutaneously express higher CD10 levels, whereas
cells from visceral adipose express higher CD200 levels [56].
AdMSCs are extracted from processed lipoaspirates, usually
involving collagenase digestion, and then sorted from a SVF.
AdMSCs also may not emerge until after extensive culture of
the SVF. In one study, the unsorted SVF had a similar thera-
peutic effect to AdMSCs in a renal I/R injury model [30], but
further comparisons of all these cell types are warranted.
Recognizing that MSCs were heterogeneous populations
and differed between labs, the International Society for Cellu-
lar Therapy (ISCT) recommended basic standards for pheno-
typic and functional characterization of these cells [57]. By
ISCT deﬁnition, MSCs are plastic-adherent; identiﬁed by
CD73+, CD90+, CD105+, CD11b− /CD14−, CD19− /CD79a−,
CD34−, CD45−, and HLA-DR−; and can differentiate into osteo-
blasts, adipocytes, and chondrocytes. Although this helps to
delineate an identity of MSCs, cells with this identity are still
enormously heterogenous within and between populations
and may contain pro-inﬂammatory and expected anti-
inﬂammatory phenotypes [58]. Recognition of the problem of
ongoing heterogeneity led to development of immune func-
tional assays for MSC as potency release criteria by ISCT [59].
MSC populations used in the clinic to date are not clonally
derived. For autologous therapies, identity is often not
deﬁned. For nonclonal allogeneic, MSC identity and quality of
these cells must be evaluated for every derivation to ensure
safety and for correlation of identity and behavior [60]. Human
ESC-derived MSC may be useful to generate a better charac-
terized MSC population as well as for extending their
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proliferative potential during manufacture and have been used
successfully in preclinical lupus nephritis [61]. MSC exosomes
also have therapeutic potential in the treatment of renal dis-
ease [62]. Because of their wide study, differences between
MSC derived from different organs have been reported, but
not yet compared with the much less studied, nestin-positive
MSC isolated from kidney [19].
Translation of autologous therapies is inherently difﬁcult
because of the enormous heterogeneity of (outbred) humans,
such that autologous MSC products are by nature different from
person-to-person, contributing to the variability in therapeutic
effects. Furthermore, in many instances, human RP cells are
obtained from nephrectomized kidneys, [54] which can be
expected to be disease with a pathological microenvironment
(itself highly variable from patient to patient). Therefore, source
(including age and sex of the donor and disease state), method
of isolation and method of cell culture are all details that need
harmonization to promote stem cells as therapeutic tools. Impor-
tantly, a better understanding of preclinical models of (acute)
kidney disease is also dependent on developing a better under-
standing of human AKI [63], pointing to the importance of con-
tinuous interaction between preclinical and clinical researchers
Preclinical Animal Models of Disease
Another important aspect that can account for differences in
results and their interpretation is the animal model. A variety
of different methods are available to model clinical AKI, includ-
ing some with direct clinical homologies including I/R injury,
and renal toxic drugs (gentamycin, cisplatin, amphotericin).
Glycerol is used to generate a rhabomyolysis AKI model.
Although all of these methods generate a form of AKI, the
amount of damage is different between models, and each acti-
vates distinct molecular and cellular injury and regenerative
pathways. Importantly, not all animal strains of a species
respond to renal toxic interventions in the same way. For
example, the 129 mouse strain is highly resistant to AKI
(induced by I/R) versus C57BL mice [64].
Various preclinical models of CKD have been used to mimic
the myriad human CKDs. Although reproducing common hall-
marks of CKD—loss of renal function and the disruption of the
glomerular ﬁltration barrier (with loss of podocytes, the key
cell for renal ﬁltration)—the pathophysiology of diabetic
nephropathy compared with, for example, focal segmental glo-
merulosclerosis is quite different. Inherited CKDs, including
Alport Syndrome [65] or Pierson Syndrome [66], have yet
other patterns of glomerular injury, interstitial ﬁbrosis, and
chronic inﬂammation.
The comparison of different stem cell types in the same
experimental model is important to advance the ﬁeld, so that
the optimal, most potent cell type can be chosen for a particu-
lar renal pathology. In a cisplatin model of AKI, comparison of
MSCs from allogeneic rat bone marrow, human adipose tissue,
and human amniotic ﬂuid showed differences in potency and
also differences in the kinetics of the therapeutic effect [67].
Identifying an animal model that fully recapitulates human
kidney disease and reﬂects the human response to stem cell
therapy is a problem across all of translational medicine and not
likely to be solved soon, pointing to the need to examine engi-
neered organ models [68] in parallel with clinical studies, as well
as mathematical modeling of disease [69, 70] and regeneration.
Route of Administration, Organ Localization, Survival
and Toxicity
Several receptor–ligand systems are involved in the homing of
stem cells to diseased organs. Expression of stromal cell-derived
factor (SDF) and hyaluronic acid by damaged tissue are involved
in stem cell recruitment; stem cells expressing chemokine
receptors follow a SDF gradient to diseased tissue [70, 71].
Increased vascular permeability that follows inﬂammation may
also contribute to tissue localization of administered cells. In
addition to pathology-associated homing patterns, migration
and localization of stem cells are dependent on the route of
administration. Stem cells can be injected by many different
routes (Table 1) and depending on route of delivery, may local-
ize or become trapped in non-target organs, such as lungs or
liver. Obviously, localization following tail vein injection will be
different than after injection into the renal artery. In the ﬁrst
case, stem cells circulate systemically before reaching the kid-
ney. Therefore, stem cell biodistribution is important to study
when evaluating the potency and efﬁcacy of a stem cell therapy:
The numbers and precise localization of cells in the target organ
are fundamental factors in renoprotective effects.
Stem cells have different capacities for integrating into tar-
get organs, as we showed with AFSC [37]. We found almost
no integration in a CKD model (after 5 days) and very low inte-
gration in ATN models despite a positive therapeutic signal.
Various approaches to enhancing integration of stem cells may
lead to more potent therapies, depending on stem cell type.
Feng et al. showed that modiﬁcation of AFSCs with SIRT3
increased engraftment [72]. Others [73] suggest that AFSCs
transfected with GDNF promotes differentiation into endothe-
lial cell lineages.
Survival after injection is a critical factor in stem cell thera-
pies; survival is often challenging in a toxic disease microenvi-
ronment. Data from a multitude of animal and clinical models
show a wide variety of survival kinetics, complicated by the
lack of easy-to-use, non-toxic, and inexpensive methodologies
to track cells after injection. Some studies report a short-term
integration, others reported a longer residence and these
results are certainly dependent on stem cell type, on route of
delivery, and details of the target pathology. Another general-
ity important issue across cell types is that cells delivered in
suspension are subject to anoikis if they do not quickly anchor,
hence the development of 3D or patch grafts for stem cell
therapeutics. It is difﬁcult to follow cell survival in humans of
course, because repeat biopsies are not possible. For MSC,
across models and routes of delivery, the cells are usually
cleared rapidly from the body, although therapeutic effect can
outlast residence time, which has implications for understand-
ing their mechanism of action. At this point, there are not
much data to determine whether a prolonged time of survival
time enhances renal regenerative response to a particular cell
therapy. Nonetheless, embedding cells in a matrix [74] can
enhance their survival (preventing anoikis), residence time,
and so such engineered adjuncts of therapy are under active
investigation (but beyond the scope of this review). Many
other approaches have been proposed for in vitro manipula-
tions to prepare cells before delivery to increase survival
including statins [75] and hypoxic preconditioning [76]. These
methods also require standardization so that results can be
compared across studies.
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Persistence of stem cell activity may require repetitive dos-
ing, especially likely for CKDs. Very few papers describe the
effects of multiple injections in vivo, and initial clinical trials
are usually designed around safety of a single dose. It is also
important to document the kinetics of kidney dysfunction and
repair after each injection, which is likely to be different from
injection to injection. Furthermore, although not widely recog-
nized the immune response may be primed after a ﬁrst MSC
injection, resulting in alloimmunization [77] with potential loss
of therapeutic efﬁcacy.
Safety and toxicity of cell therapies is difﬁcult to translate
from animal to human models because of the model con-
straints. Often when human cells are studied, the animal
models are immunodeﬁcient, limiting insights into pathological
inﬂammatory responses to the cells. Although MSCs are trans-
planted across allogeneic or even xenogeneic barriers, some
animal studies have clearly shown that cellular and humoral
responses against xenogeneic MSCs can develop in immuno-
competent recipients [78]. Mobilization, reprogramming, or
other manipulations of stem cells can trigger unintended
events that carry risk for recipients. Cell culture conditions can
contribute to toxicity. For example, a senescent population of
cells can emerge in an over-passaged line, resulting in cells
that behave differently, even antithetically, to the original pop-
ulation [60]. Expansion of pluripotent stem cells is associated
with acquisition of mutations, including those in the gene
encoding the tumor suppressor P53, leading to a recommen-
dation that genetic characterization of these lines and their
differentiated cell products be carried out before clinical appli-
cation [79]. Adult (nonpluripotent) stem cells can also acquire
chromosomal abnormalities with expansion [80] and so must
be monitored for these changes during cell manufacturing pro-
cesses used to generate working and master cell banks.
The risk of tumorigenesis must be considered in any appli-
cation of stem cell therapy. Given the extensive experience
with MSCs, tumorigenesis is not considered a risk of these
therapies. Some stem cells express markers also found in can-
cer stem cells or upregulated in tumors. One example is the
expression of CD133 in clear cell renal carcinoma [81], but the
application of CD133+ renal stem cells has not been associated
with development of this cancer.
The tumorigenic effect of naïve, undifferentiated iPSCs or
RPs derived from them are not really clear, as this is a relatively
new area of study, but iPSCs are deﬁned by the ability to form
teratomas. Human iPSCs directed toward a nephrogenic inter-
mediate mesoderm were effective in ameliorating murine AKI
(administered via tail vein) without apparent tumorigenesis
[40]. Osafune used iPSC-derived renal tubulogenic progenitors
to reduce tubular necrosis and dilatation, and interstitial ﬁbrosis
in a mouse I/R AKI model [41] without tumorigenesis. This same
group recently reported a selectable marker method
(CD9−CD140a+CD140b+CD271+) to enrich human iPSCs for RPs
[82]. A recent report of a protective effect of undifferentiated
naïve iPSCs administered into renal parenchyma in a rat 5/6 Nx
model conﬁrmed that undifferentiated iPSC have potential to
generate tumors; treated animals developed tumors similar to
Wilms’ tumor [83]. Concentrated iPSC-conditioned medium,
however, was shown effective in protecting from ischemic dam-
age, and this acellular product was not tumorigenic [84].
The impact of aging and of the underlying chronic disease
itself on donor stem cell function is an obvious constraint of
autologous therapies but deserves consideration for allogeneic
therapies [78]. In the lab, donor cells are usually derived from
healthy, young donors. Autologous therapy using old or dis-
eased stem cells may have more limited therapeutic beneﬁt
for many reasons including reduced numbers, proliferation,
differentiation capacity, and changed secretome proﬁles.
Chronic inﬂammation, diabetes and uremic toxins also affect
the host microenvironment [32] in kidney disease. The use of
markers of senescence, such as telomerase, may be helpful in
phenotyping therapeutic cells. Along the same lines, diseases
that primarily affect older humans are usually studied in young
animal models, which may overestimate the potency of the
therapeutic effect.
These considerations are highlighted by a large multicenter
international trial of MSC targeting AKI after cardiac surgery.
This well-designed study of 156 subjects showed no beneﬁt of
MSC in shortening time to renal recovery, need for dialysis, or
mortality. In fact, although not statistically signiﬁcant, subjects
treated with MSC had worse outcomes [85]. The authors cited
many reasons why MSCs failed to show beneﬁt including tim-
ing of the MSC treatment (late rather than preventive), the
multifactorial underpinnings of AKI after cardiac surgery, lon-
ger bypass times in the MSC-treatment group, and pre-existing
renal dysfunction in the study population. They did not note
the important fact that cardiac surgery patients are usually
old, often with hypertension and/or diabetes, and this pheno-
type is virtually never reﬂected in the usual animal models of
I/R injury using young animals without pre-existing chronic
vascular risk factors that damage kidneys over time.
Reagents Used to Study Stem Cell Biology:
Interpretation of the Data
The FDA requires that reagents used in isolation, expansion,
and manipulation of cells for therapeutic use are strictly
deﬁned to assure consistent quality and safety of the ﬁnal cell
product. We believe that the choice of reagents in analysis of
cells during preclinical development is also extremely impor-
tant and often under-emphasized. For example, interpretation
of the results (speciﬁcally related to stem cell integration) can
be difﬁcult if cell surface and membrane dyes are used. These
dyes are diluted over time by proliferation of the labeled pop-
ulation or if they fuse to host cells, limiting interpretation of
biodistribution studies.
Antibodies for western blots are also a huge problem
throughout biology. In our hands, for example, evaluating de
novo deposition of collagen IVα3,α4,α5 within the glomerular
basement membrane by injected stem cells was challenging, as
we found only one antibody that distinguishes this collagen tri-
mer. Protocol adjustments and accurate interpretation of the
results require knowing if the antibody is directed to a surface
versus an intracellular epitope. Secondary antibody ﬂuorescent
labeling and its detection by ﬂow cytometry can layer additional
complexity onto data interpretation. The ﬂuorescent signal on a
ﬂow cytometer must be gated and deﬁned by thresholds that
can be very nuanced, especially when the population of interest
is rare. Variation between machines, the quality of the ﬂuoro-
chrome (between manufacturers and lots), and the binding
afﬁnity of the secondary antibody to the primary antibody will
alter detection and analysis by ﬂow cytometry.
In summary, we believe that cell source including quality of
the sample, age, sex and disease status (phenotype) of the
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donor, and so forth, methods of cell isolation and culture, pre-
clinical models, route of administration, biodistribution, survival,
toxicity, and reagents used during pre-clinical analysis all require
detailed consideration, documentation, and ideally harmoniza-
tion, to advance stem cell therapies. The quality measures
required for clinical application should be adapted as much as
possible during preclinical development of stem cell products.
STEM CELLS AND CLINICAL TRIALS FOR RENAL DISEASE
Stem cells (from any source) are an incredible research tool
for understanding kidney regeneration. Once injected in vivo,
they can serve as a cellular “indicator” of markers of disease
progression and regression, by comparing molecular and histo-
logical changes before and after their delivery. On the other
hand, when stem cells are being developed for therapies,
there is less emphasis on the mechanisms of action and more
on quantifying clinical endpoints of therapy.
Advancing Clinical Trials of Stem Cells for Renal
Disease
Most stem cell clinical trials for renal disease use MSCs, which
are not truly regenerative therapies. As noted earlier, MSCs differ
qualitatively from person-to-person and between labs and man-
ufacturers, in addition to the heterogeneity inherent in different
tissue sources (marrow, adipose, etc), and heterogeneous kidney
diseases are studied. It is therefore not possible to do a rigorous
meta-analysis of MSC trials for renal disease [60], but some of
the details of these studies hold important lessons.
The ﬁrst trials using bone-marrow derived MSCs suggested
that these cells could be given safely. In cardiac surgery
patients, at high risk of post-operative AKI, MSC administration
was safe and well-tolerated [86]. Autologous AdMSCs given via
the renal artery to patients with renovascular disease were
safe and improved renal blood ﬂow and oxygenation 3 months
after treatment (n = 14) compared with medical therapy alone
(n = 14) [87]. In the ﬁrst placebo controlled, two-dose trial of
allogeneic BM-derived mesenchymal precursor cells for
patients with diabetic nephropathy (still with only n = 10/
group), cells were again safe and did not elicit an immune
response; this underpowered study suggested a trend toward
a therapeutic effect at 12 weeks [88]. A study of six autosomal
dominant polycystic kidney disease patients given autologous
BM-MSCs intravenously again conﬁrmed safety of these cells,
but renal function was not improved 1 year after therapy [89].
A study of 30 patients with heterogeneous CKDs including
10 renal transplant patients suggested renal function improve-
ment at 6 months after autologous BM-MSC [90].
Complications have occurred with these “benign” cells.
Administration of umbilical cord-derived MSCs to two renal
transplant patients was complicated by thrombosis of the periph-
eral vein injection site [91], likely a function of inadequate pre-
vention of cell clumping. Another case report suggested that
AdMSCs worsened renal function in a patient, whose CKD had
been stable. In this case, renal biopsy suggested a massive inﬂam-
matory response including cells expressing surface markers of
the presumed stem cell product [92]. As noted earlier, a uniquely
large and well-designed international study of MSC for AKI in the
context of cardiac surgery was halted when the treated group
appeared to fare worse than untreated controls [85].
In summary, MSC clinical trials target a wide variety (and
stage) of kidney diseases; trials are generally small, so that the
clinical beneﬁt of MSC therapy for AKI or CKD has not yet
been demonstrated. Only a few studies have long follow-up: A
study of autologous BM-MSCs in 30 CKD patients showed ben-
eﬁt to renal function [93] out to 18 months. Together a review
of these studies conﬁrms our bias that it will be necessary to
reduce the confounding variables (in cells, preclinical models,
and human disease phenotyping) that contribute to difﬁculty
interpreting and comparing clinical trial results. Often, for pro-
prietary reasons, details needed to compare clinical studies
rigorously, are simply not available to researchers.
Standardized Stem Cell Protocols: Available
Repositories of Different Cell Sources
Standardized cell lines (and derivation and characterization
protocols) could be useful for data pooling by the research
community, perhaps under the auspices of a national funding
agency. Although challenging to execute, standardized lines
and protocols would ultimately beneﬁt the research commu-
nity and patients, although may be opposed by biotechnology
companies competing in this space with proprietary lines. For
now, peer-reviewed journals should provide adequate space to
present key biological authentication statements (as requested
in NIH applications). Room for detailed supplemental protocols
with speciﬁc focus on reagent details used for cell isolation
and culture, in addition to a very detailed description (espe-
cially for human cells) of donor sex/age and exclusion/inclu-
sion criteria will be helpful for interpreting results between
labs. Information about population doubling (and time) at the
time of preclinical application should be provided, along with
cell density at passage, clonal versus nonclonal generation,
and culture media protocols. These very tedious details are
often missing in the literature. Nevertheless, this information
is extremely critical to facilitate a smooth transition from aca-
demic labs to commercial manufacturing.
Recently, the need for a standard MSC ruler whose pur-
pose would be to “serve as a common calibration tool and
provide a central data point” was raised [94]. This interesting
approach requires the deﬁnition of reference cell material
needed to generate baseline characterization data (phenotype;
karyotype; gene expression proﬁle; cytokine secretion proﬁle;
and functional read-outs) to be set as general common refer-
ence. Different sources will likely contribute to determine the
standard MSC cell ruler, including data collection from large
sets of cell materials, single-donor cell lines from cell banks,
immortalized cell lines, and iPS-derived self-renewing lines
[95]. Once the standards are deﬁned, ongoing management of
a repository will require further funding and oversight by a
qualiﬁed agency, but it is important for moving the ﬁeld for-
ward. A central cell bank available to all researchers would
also help to make the results from different labs comparable,
and so synergize research efforts. To this end, the NIH estab-
lished a bank of clinical grade marrow-derived stromal cell
products in 2012 [96]. The article describing the bank has only
been cited 18 times, suggesting that the bank has not been
used widely as a resource, despite its availability. Another sug-
gestion is to identify optimal human pluripotent cell lines for
use in preclinical kidney disease studies. Individual embryonic
stem cell lines have marked differences in propensity to differ-
entiate down a speciﬁc lineage [97] as do iPSC lines. Given the
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numbers of iPSC banks, it may be possible to identify a line
with high propensity to generate RPs for study in a number of
kidney disease models across different labs.
Stem cell populations (like MSCs) behave differently in dif-
ferent disease contexts, so that efﬁcacy and potency testing
must be application speciﬁc. Molecular characterization of stem
cells and their preclinical efﬁcacy do not predictably translate
into clinical beneﬁt. Co-culture of the therapeutic stem cell
product with speciﬁc renal cell types, and in mixed lymphocyte
reactions, is useful for further characterizing the stem cells
beyond expression analysis. Standard culture tests that may also
inform mechanism of action include the induction of tubular
epithelial cell proliferation, survival in co-culture, or reduction
of lymphocyte proliferation. For example, an in vitro model of
IL-10 release from blood cells has been suggested as a potency
assay for MSC immunomodulation [98]. For some applications,
the immunomodulatory function of MSCs can be assayed using
their modulation of a cytokine signature in blood mononuclear
cells [99, 100]. Co-cultures can be designed based on antici-
pated mechanisms of action, such as tube formation assays if
vasculogenesis is important in the therapeutic response.
Standard Preclinical Small and Large Animal Models
No animal model completely recapitulates human disease. Fur-
thermore, the precise pathophysiological features of various
animal models of kidney disease require different endpoints for
analysis, and the animal model often constrains the numbers of
endpoints that can be examined, especially for histopathologi-
cal endpoints requiring biopsy or necropsy. For mouse models,
frequent blood sampling is difﬁcult; surgical manipulation, con-
sidering size alone, is also technically challenging; and miniatur-
ized continuous physiological monitoring is expensive and not
readily available. For these reasons and because murine disease
often does not capture the heterogeneity of human disease,
mouse models are usually insufﬁcient alone for justifying
advancement to clinical application, especially of a novel ther-
apy. In addition, renal structure and function (physiology) differ
among species and strains, and caution is warranted when
extrapolating experimental data from one animal model to
another (and to humans). For these reasons, large animal
models remain important for translation and should be charac-
terized as deeply as possible by experts in renal physiology and
veterinary disease. Large animal models, until more sophisti-
cated virtual models are available, are necessary to aid in estab-
lishing dose, scalability, safety and toxicity, and route of
delivery. We realize that using larger animal models is compli-
cated and expensive, but strong collaborations between
different groups of experts (researchers and veterinarians) can
improve the cost:beneﬁt ratio of large animal studies.
The best animal models for acute and chronic kidney dis-
eases need to be further characterized for the research com-
munity. For example, researchers using a strain of mice in a
particular disease must understand the kinetics of disease
including blood markers, proteinuria, progression of histologi-
cal damage in the tubules versus glomerulus, and so forth, in
the untreated disease in that particular strain. Ideally compar-
ative detailed studies of AKI and CKD models between strains
could move the ﬁeld forward, but funding for these kinds of
studies is difﬁcult to obtain. A select committee of experts
(researchers, clinicians, statisticians, etc.) to develop best prac-
tices for preclinical study design, including stem cell source
and disease model, and set standards for methods of isolation,
culture, administration, analysis, could be better fostered by
professional societies and/or funding agencies.
CONCLUSION
An enormous body of preclinical literature supports the appli-
cation of stem cells to treat renal disease, but no safe, scal-
able and effective therapies have yet emerged from this
research effort. To get through the current research bottle-
neck, we believe that organized collaboration of the research
community—with help from professional, standards and fund-
ing agencies—s necessary, with the goal of developing har-
monized protocols for isolation, characterization, and culture
of stem cells, as well as full characterization of preclinical
models of kidney disease. Collaboration and harmonization
are necessary changes to the research culture, which should
synergize experimental efforts of individual groups by making
data comparable from lab to lab, enhancing statistical power,
to help speed translation of stem cell therapies for the major
unmet need in kidney diseases.
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